

Curriculum Vitae of David B. Ross, M.D., Ph.D., M.B.I.

Personal data

Citizenship: United States

Address: 212 Stony Run Lane; Baltimore, MD 21210

Telephone: (301) 500-8557

E-mail: rossmdpharmaexpert@gmail.com

Education

1980 B.S. *cum laude* (Molecular Biophysics and Biochemistry), Yale University

1985 M.S. (Biochemistry), New York University

1988 Ph.D. (Biochemistry), New York University. Thesis advisor: Edward Ziff, Ph.D. Thesis title: "Defective processing of human adenovirus 2 messenger RNAs during abortive infections in monkey cells."

1988 M.D., New York University School of Medicine

2008 Graduate Certificate in Biomedical Informatics, Oregon Health and Sciences University

2012 Master of Biomedical Informatics Oregon Health and Sciences University. Advisor: Judy Logan, M.D. Capstone title: "An antibiogram data model and implementation schema."

Post-doctoral training

1988-1991 Resident, Internal Medicine, NYU Medical Center/Manhattan

1991-1994 Fellow, Infectious Disease Section, Department of Internal Medicine, Yale University School of Medicine

1992-1994 Research Fellow, Division of Infectious Diseases, Department of Pediatrics, Yale University School of Medicine

FDA Training

1996 CDER Regulatory Science Course

1996 CDER New Reviewer's Workshop

1997 CBER Clinical Trials Course

FDA Training (cont.)

- 1998** CDER Basic Statistical Methods Course; JMP Training
- 2003** FDA Pharmacogenomics in Drug Development Workshop
- 2005** FDA Transcriptional Microarrays Course

Expert Witness Training

- 2014** How to be an Effective Expert Witness. SEAK, Inc., Feb 8-9, Clearwater, FL
- 2015** National Expert Witness Conference. SEAK, Inc., Apr 23-26, Washington, DC
- 2016** Advanced Trial Skills for Expert Witnesses. SEAK, Inc., May 12-13, Chicago, IL
- 2016** National Expert Witness Conference. SEAK, Inc., May 14-15, Chicago, IL
- 2018** How to Excel at Your Expert Witness Deposition. SEAK, Inc., Dec 1-2, Naples, FL

Professional Experience

- 2006 –** National Program Executive Director, HIV, Hepatitis, and Related Conditions Programs, Office of Specialty Care Services, Veterans Health Administration, US Department of Veterans Affairs (VA)
- 2005-2006** Associate Director for Regulatory Science, Office of Oncology Drug Products, Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA)
- 2004-2005** Deputy Director, Office of Drug Evaluation VI, CDER, FDA
- 2000-2004** Medical Team Leader, Division of Anti-Infective Drug Products (DAIDP), CDER, FDA
- 1999-2004** Senior Medical Reviewer, DAIDP, CDER, FDA
- 1999** Acting Medical Team Leader, DAIDP, CDER, FDA
- 1998 –** Staff Physician, Infectious Disease Section, Washington, DC VAMC
- 1996-2004** Medical Officer, DAIDP, CDER, FDA

Professional Experience (cont.)

- 1995-1996** Associate Physician, Department of Pediatrics, Yale-New Haven Hospital; Attending Physician, Pediatric AIDS Clinic, Yale-New Haven Hospital
- 1994-1996** Staff Physician, Infectious Disease Section, West Haven, Connecticut VAMC
- 1993-1997** Infectious Disease Consultant, HIV-in-Prisons Program, Yale University School of Medicine
- 1991-1993** Emergency Room Attending (Medical Officer of the Day), Manhattan VAMC

Academic Positions

- 2008 –** Associate Clinical Professor of Medicine, George Washington University School of Medicine and Health Sciences
- 2000-2008** Assistant Clinical Professor of Medicine, George Washington University School of Medicine and Health Sciences
- 1995-1996** Instructor, Department of Pediatrics (Infectious Diseases), Yale University School of Medicine
- 1992-1995** Lecturer, Department of Molecular Biophysics and Biochemistry, Yale University
- 1989-1991** Teaching Assistant, Department of Medicine, NYU School of Medicine

Honors and awards

- 2006** CDER Excellence in Communication Award (OODP)
- 2005** CDER Excellence in Leadership Award (ODE VI)
- 2004** CDER Team Excellence Award (Ketek Review Team)
- 2003** CDER Team Excellence Award (CDER TOPOFF 2 Exercise Team)
- 2002** FDA Award of Merit (CDER Counter-Terrorism Response Team)
- 2000** FDA Commendable Service Award (Linezolid Review Team)
- 1999** CDER Group Recognition Award (Inter-Divisional Working Group on Antibiotic Resistance)

Honors and awards (cont.)

- 1997** CDER Team Excellence Award (Maxipime® Review Team)
- 1997** CDER Excellence in Communication Award (ODE IV/PhRMA Working Group)
- 1994-1996** Pediatric AIDS Foundation Scholar
- 1992-1994** Patrick and Catherine Weldon Donaghue Medical Research Foundation Fellow
- 1980-1987** National Institutes of Health Medical Scientist Training Fellow
- 1976** U.S. Presidential Scholar

Licenses and Certification

- 1989** Diplomate, National Board of Medical Examiners
- 1989** Licensed, New York State Board for Medicine (inactive)
- 1992** Diplomate in Internal Medicine, American Board of Internal Medicine (ABIM)
- 1993** Licensed, State of Connecticut Department of Health Services (inactive)
- 1994** Diplomate in Infectious Diseases, American Board of Internal Medicine (ABIM)
- 1998** Licensed, State of Maryland Board of Physician Quality Assurance (current)
- 2002** Recertification in Internal Medicine, ABIM
- 2004** Recertification in Infectious Diseases, ABIM
- 2015** Recertification in Infectious Diseases, ABIM

Membership in Professional Societies

- American College of Physicians
- Infectious Diseases Society of America
- Antimicrobial Use and Clinical Trials Committee (2001 – 2003)
 - Antimicrobial Availability Task Force (2003 – 2005)

FDA Advisory Committee and Workshop Presentations

- Mar 2006** Oncology Drugs Advisory Committee (ODAC): Non-clinical Studies for Initiating Phase 1 Studies in Oncology: Small Molecules vs. Biologics

FDA Advisory Committee and Workshop Presentations (cont.)

- Jun 2004** Public Workshop on Strategies for Developing Therapeutics that Directly Target Anthrax and its Toxins: Clinical Safety Testing in Healthy Volunteers
- Apr 2004** Public Workshop on Antimicrobial Drug Development: Bacteremia as an Indication
- Oct 2003** Anti-Infective Drugs Advisory Committee (AIDAC): Bacteremia as an Indication for Antibiotic Foot Infections
- Feb 2002** AIDAC: Developing Drugs for Resistant Pathogens
- Apr 2001** AIDAC: Ketek (telithromycin)
- Mar 2000** AIDAC: Zyvox (linezolid)
- Oct 1999** AIDAC: Guidance for Industry: Catheter-related blood-stream infections: Developing antimicrobials for treatment
- Jul 1999** Federal interagency meeting – Development of a Public Health Action Plan to Combat Antimicrobial Resistance
- Oct 1998** AIDAC: Bacteremia as an Indication
- Jul 1998** FDA-Industry Workshop on Anti-Infectives for Resistant Bacteria
- Feb 1998** AIDAC: Guidance for Industry. Empiric therapy of febrile neutropenia. Developing antimicrobials for treatment
- Mar 1997** AIDAC: Maxipime (cefepime) for empiric therapy of febrile neutropenia
- Nov 1996** AIDAC (Closed meeting)

FDA Special Assignments

- 2004 – 2005** Anthrax Toxin Therapeutics Guidance Working Group (chair)
- 2004 – 2006** Subpart D Working Group
- 2004 – 2006** Lead in Drug Products Working Group
- 1999 – 2002** Committee for the Advancement of FDA Science
- 1999** Catheter-related Bloodstream Infections Guidance Working Group (chair)
- 1997 – 1999** CDER ODE IV Evaluability Criteria Working Group

FDA Special Assignments (cont.)

- 1997** CDER ODE IV Working Group on Drugs of Last Resort (chair)
- 1997** CDER ODE IV Task Force on Human Antibiotic Use in Animals
- 1997** CDER ORM Information Technology Working Group
- 1997** CDER ODE IV/PhRMA Working Group on Targeted Package Inserts
- 1997** CDER Office of Information Technology Coordinating Committee

Presentations

Hepatitis C in the Department of Veterans Affairs. American Correctional Association All-Health Authority Training Symposium, November 15, 2018.

Ending the Epidemic: Veterans Administration Strategy for Hepatitis Care. Kentucky 4th Annual Viral Hepatitis Conference, July 27, 2017.

HIV in VA – Where are we? Albany Medical College, World AIDS Day Conference, December 4, 2016.

Hepatitis C in VA. U.S. Department of Health and Human Services. World Hepatitis Day Conference. October 28, 2015.

Hepatitis C Drug Costs. Testimony at Hearing before Senate Veteran Affairs Committee. 113th Congress, Second Session. December 3, 2014.

Hepatitis C in VA. National Association of State Medicaid Directors. November 6, 2014.

HIV Testing in the U.S. Department of Veterans Affairs. Pennsylvania Department of Public Health Conference on HIV surveillance. October 30, 2014.

Hepatitis C and Cirrhosis. VHA National Transplant Conference. April 23, 2014.

Viral Structure, Genetics, and Pathogenesis. George Washington University School of Medicine and Health Sciences, Medical Microbiology course. November 6, 2013.

VHA's National Hepatitis C Program. Briefing for House and Senate Veterans Affairs Committee staff. October 11, 2013.

Presentations (cont.)

Hepatitis C in the Department of Veterans Affairs. Hospital of the University of Pennsylvania Grand Rounds. September 18, 2013.

Restructuring the VHA's Field-Based HCV Program. Presentation to the VHA National Leadership Council. August 20, 2013

Viral Structure and Replication. George Washington University School of Medicine and Health Sciences, Infection and Immunity course, March 20, 2013.

Viral Structure, Genetics, and Pathogenesis. George Washington University School of Medicine and Health Sciences, Medical Microbiology course. October 31, 2012.

VHA's National HIV Program. Briefing for staff in office of Representative Barbara Lee (9th Congressional District, California). March 15, 2012

Viral Structure, Genetics, and Pathogenesis. George Washington University School of Medicine and Health Sciences, Medical Microbiology course. October 26, 2011.

HIV Testing in VA. Indian Health Service HIV/STD Workshop, Scottsdale, AZ, June 2, 2011.

HCV in the VA in 2011: Where are we? VISN 16 Pharmacy Benefits Management Strategic Planning Meeting, Ridgeland, MS, March 9, 2011.

Viral Structure and Replication. George Washington University School of Medicine and Health Sciences, Infection and Immunity course, February 8, 2011.

HIV and HCV Rating Disabilities in Veterans with Service-Connected HIV or HCV. Veterans Benefit Administration Service-Connected Rating Disability Forum, Scottsdale, AZ, January 31, 2011.

HCV in the VA in 2010: Where are we? Infectious Disease Grand Rounds, Durham Veterans Affairs Medical Center, December 13, 2010.

Viral Structure, Genetics, and Pathogenesis. George Washington University School of Medicine and Health Sciences, Medical Microbiology course. October 28, 2010.

HCV in the U.S. Department of Veterans Affairs. Professor *pro tem* Lecture, University of Mississippi Medical Center, September 22, 2010.

Hepatitis C Overview. Liver Disease for VA Primary Care Providers meeting, New Orleans, June 16, 2010.

Presentations (cont.)

HIV in the VA in 2010: Where are we? Grand Rounds, Temple (TX) Veterans Affairs Medical Center, June 10, 2010.

HCV in the VA in 2010: Where are we? Grand Rounds, Dallas Veterans Affairs Medical Center, January 27, 2010.

HCV in the VA in 2009: Where are we? Grand Rounds, Orlando Veterans Affairs Medical Center, December 2, 2009.

Viral Structure, Genetics, and Pathogenesis. George Washington University School of Medicine and Health Sciences, Medical Microbiology course. October 29, 2009.

Impact of Comorbidities on the Management and Prognosis of Chronic Liver Disease. Presented at **The Dawn of a New Era: Transforming our Domestic Response to Hepatitis B & C**, September 14, 2009.

HCV in the VA in 2009: Where are we? Grand Rounds, Bay Pines Veterans Affairs Medical Center, September 2, 2009.

HIV Care in the Department of Veterans Affairs. Grand Rounds, University of Mississippi Medical Center, July 21, 2009.

HCV in the VA in 2009: Where are we? Grand Rounds, Pensacola, Florida Joint Ambulatory Care Center, June 25, 2009.

HIV in the VA in 2009: Where are we? Grand Rounds, Salem, Virginia Veterans Affairs Medical Center, March 13, 2009.

HIV in the VA in 2009: Where are we? Grand Rounds, Gulf Coast Veterans Healthcare System, March 12, 2009.

Viral Structure, Genetics, and Pathogenesis. George Washington University School of Medicine and Health Sciences, Medical Microbiology course. November 7, 2008.

Ketek: Lessons Learned. Clinical Operations Retreat, May 8, 2008.

Pharmacogenomics: A Guide for the Perplexed. Grand Rounds, Sinai Hospital (Baltimore, MD). March 27, 2008.

Ketek Clinical Study Fraud: What did Aventis Know? Testimony at Hearing Before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce. 110th Congress, Second Session. February 13, 2008.

Viral Structure, Genetics, and Pathogenesis. George Washington University School of Medicine and Health Sciences, Medical Microbiology course. November 2, 2007.

Presentations (cont.)

FDA: Inside the Black Box. George Washington University School of Public Health and Health Services. October 29, 2007.

Viral Structure, Genetics, and Pathogenesis. George Washington University School of Medicine and Health Sciences, Medical Microbiology course. November 3, 2006.

The Good, the Bad, and the Unbelievable: Interpreting Clinical Trials. Grand Rounds, Washington, D.C. VA Medical Center. October 25, 2006.

Oncology Biomarkers for Safety and Efficacy. 2006 International Conference on Drug Development. February 15, 2006

Pharmacogenomics: A Guide for the Perplexed. Grand Rounds, Washington, D.C. VA Medical Center. January 18, 2006.

Issues in accelerated approval. 12th Biomedical Applied Statistics Symposium. November 9, 2005.

FDA's Critical Path Initiative. 2005 Annual Meeting of the Association of Clinical Research Professionals. November 2005

Natalizumab: A case study in classic risk-benefit analysis. Biotechnology Industry Organization annual meeting. June 21, 2005.

Therapeutic Biologics. Pharmaceutical Education and Research Institute course on "Biologics Drug Development." April 11, 2005

Therapeutic Biologics. University of Maryland, Baltimore course on "Drug Development Processes and Regulatory Approaches." March 23, 2005.

FDA's Critical Path Initiative. Association of Clinical Research Professionals (Connecticut chapter). March 9, 2005.

Bone and Joint Infections. GWUMC/Washington DC VAMC Fellows Lecture program. December 23, 2004.

Viral Structure, Genetics, and Pathogenesis. George Washington University School of Medicine and Health Sciences, Medical Microbiology course. November 5, 2004.

Viral Structure, Genetics, and Pathogenesis. George Washington University School of Medicine and Health Sciences, Medical Microbiology course. November 3, 2003.

Bone and Joint Infections. GWUMC/Washington DC VAMC Fellows Lecture program. June 26, 2003.

Presentations (cont.)

Viral Structure, Genetics, and Pathogenesis. George Washington University School of Medicine and Health Sciences, Medical Microbiology course. November 4, 2002.

Bone and Joint Infections. GWUMC/Washington DC VAMC Fellows Lecture program. May 23, 2002.

The Role of Antibiotics in Upper Respiratory Tract Infections. Grand Rounds, Washington, D.C. VA Medical Center. February 6, 2002.

Clinical Trials – the FDA perspective. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. December 18, 2001.

Catheter-related Bloodstream Infections: Developing Antimicrobial Drugs for Treatment. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. December 16, 2001.

Geriatric Drug Development. American College of Toxicology, 22nd Annual Meeting. November 6, 2001.

Viral Structure, Genetics, and Pathogenesis. George Washington University School of Medicine and Health Sciences, Medical Microbiology course. November 2, 2001.

Don't Let Your Patients Push You to Prescribe: Managing the Use of Antibiotics. Maryland State Medical Association 2001 Convention. September 8, 2001.

Cotrimoxazole and Lactation. CDER Scientific Rounds. April 19, 2001

Treatment of Gram-positive Infections in the New Millennium. Washington, D.C. VA Medical Center. February 8, 2001.

Viral Structure, Genetics, and Pathogenesis. George Washington University School of Medicine and Health Sciences, Medical Microbiology course. November 1, 2000.

Comparators in Clinical Trials. 38th Infectious Diseases Society of America Annual Meeting. September 7, 2000.

New Antimicrobials for Drug-Resistant Gram-Positive Organisms. Washington, D.C. VA Medical Center. May 26, 2000.

Bone and Joint Infections. GWUMC/DC VAMC Fellows Lecture program. May 18, 2000.

Viral Structure and Genetics. George Washington University School of Medicine and Health Sciences, Medical Microbiology course. November 16, 1999.

Presentations (cont.)

Clinical Trials: The FDA Perspective. George Washington University Medical Center, Clinical Trials course. October 1, 1999.

Use of alternative definitions of clinical response in trials of empiric anti-bacterial therapy of febrile episodes in neutropenic patients. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. September 27, 1999.

Skin and Soft Tissue Infections. Washington Hospital Center/Washington VAMC Fellows Lecture program. December 17, 1998.

Computer-Assisted New Drug Applications. FDA Office of Commissioner's Administrative Conference. December 6, 1996.

FDA: Inside the Black Box. Yale University, Department of Molecular Biophysics and Biochemistry, November 12, 1996.

Publications**Books and Book Chapters**

1. **Ross D, ed.** Primary Care of Veterans with HIV, revised edition. (Washington, DC: US Department of Veterans Affairs), 2019.
2. **Ross D, ed.** Primary Care of Veterans with HIV edition. (Washington, DC: US Department of Veterans Affairs), 2009.
3. **Ross D** and Trevino S. Bacteremia and sepsis. *In* Textbook of Diagnostic Microbiology, 8th edition (New York: W.B. Saunders), 2007. Eds. C. Mahon and G. Mandel.

Published Articles

1. Matecki A, Gregoire B, Beste LA, Varley CD, Lowy E, Cartwright EJ, Morgan TR, **Ross, DB**, Rozenberg-Ben-Dror K, Maier MM. Analysis of Repeat Hepatitis C Viremia After Sustained Virologic Response in a Large Cohort of U.S. Veterans. *Clin Inf Dis*. <https://doi.org/10.1093/cid/ciaf008>. Epub 2025 Jan 9.
2. Kim CW, Haji M, Lopes VV, Halladay C, Sullivan JL, **Ross D**, Slazinski K, Taveira TH, Menon A, Gaitanis M, Longenecker CT, Bloomfield GS, Rudolph JL, Wu WC, Erqou S. Variations in antihypertensive medication treatment and blood pressure control among Veterans with HIV and existing hypertension. *Am Heart J*. 2024 Dec;278:48-60. doi: 10.1016/j.ahj.2024.08.009. Epub 2024 Aug 29. PMID: 39216692.

Published articles (cont.)

3. Maier M, Beste LA, Lowy E, Hauser RG, Van Epps P, Yakovchenko V, Rogal S, Chartier M, **Ross D**. Veteran's Health Administration HIV Care Continuum: 2019 vs 2022. *Open Forum Infect Dis*. 2024 Jul 11;11(8):ofae382. doi: 10.1093/ofid/ofae382. PMID: 39086463; PMCID: PMC11288371.
4. Varley CD, Lowy E, Cartwright EJ, Morgan TR, **Ross DB**, Rozenberg B, Ben-Dror K, Beste LA, Maier MM. Success of the US Veterans Health Administration's Hepatitis C Virus Care Continuum in the Direct-acting antiviral Era. *Clin Infect Dis*. 2024 Jun 14;78(6):1571-1579. doi: 10.1093/cid/ciae025. PMID: 38279939.
5. **Ross DB**. The decline of science at the FDA has become unmanageable. *BMJ*. 2023 May 15;381:p1061. doi: 10.1136/bmj.p1061. PMID: 37188385.
6. Villamagna AH, Beste LA, Borgerding J, Lowy E, Hauser RG, **Ross D**, Maier MM. Testing and Case Rates of Gonorrhea, Chlamydia, Syphilis, and HIV among People with Substance Use Disorders in the Veterans Health Administration. *J Addict Med*. 2023 Jul-Aug;17(4):387-393. doi: 10.1097/ADM.0000000000001134. Epub 2023 Jan 12. PMID: 37579093.
7. Soares C, Kwok M, Boucher KA, Haji M, Echouffo-Tcheugui JB, Longenecker CT, Bloomfield GS, **Ross D**, Jukowtiz E, Sullivan JL, Rudolph JL, Wu WC, Erqou S. Performance of Cardiovascular Risk Prediction Models Among People Living With HIV: A Systematic Review and Meta-analysis. *JAMA Cardiol*. 2023 Feb 1;8(2):139-149. doi: 10.1001/jamacardio.2022.4873. PMID: 36576812; PMCID: PMC9857084.
8. Haji M, Lopes VV, Ge A, Halladay C, Soares C, Shah NR, Longenecker CT, Lally M, Bloomfield GS, Shireman TI, **Ross D**, Sullivan JL, Rudolph JL, Wu WC, Erqou S. Two decade trends in cardiovascular disease outcomes and cardiovascular risk factors among US veterans living with HIV. *Int J Cardio Cardiovasc Risk Prev*. 2022 Sep 29;15:200151. doi: 10.1016/j.ijcrp.2022.200151. PMID: 36573195; PMCID: PMC9789359.
9. Beste LA, Keddem S, Borgerding J, Lowy E, Gardella C, McFarland L, Comstock E, Fonseca GA, Van Epps P, Ohl M, Hauser RG, **Ross D**, Maier MM. Sexually Transmitted Infection Testing in the National Veterans Health Administration Patient Cohort During the Coronavirus Disease 2019 Pandemic. *Open Forum Infect Dis*. 2022 Aug 23;9(12):ofac433. doi: 10.1093/ofid/ofac433. PMID: 36514443; PMCID: PMC9452156.

Published articles (cont.)

10. Yakovchenko V, Morgan TR, Miech EJ, Neely B, Lamorte C, Gibson S, Beste LA, McCurdy H, Scott D, Gonzalez R, Park A, Powell BJ, Bajaj JS, Dominitz JA, Chartier M, **Ross D**, Chinman MJ, Rogal SS. Core implementation strategies for improving cirrhosis care in the Veterans Health Administration. *Hepatology*. 2022 Aug; **76(2)**:404-417. doi: 10.1002/hep.32395. Epub 2022 Mar 17.
11. Rozenberg-Ben-Dror K, Maier MM, Beste L, Lowy E, Chartier M, **Ross D**, Morgan TR. Improving quality of hepatitis B care in the Veterans Health Administration. *Clin Liver Dis (Hoboken)*. 2022 Jul 1; **19(6)**:203-218. doi: 10.1002/cld.1237.
12. Erqou S, Papaila A, Halladay C, Ge A, Liu MA, Jiang L, Dalrymple A, Shah NR, Miech E, Virani SS, Zullo AR, Shireman TI, Longenecker CT, **Ross D**, Sullivan JL, Wu WC, Rudolph JL. Variation in Statin Prescription among Veterans with HIV and Known Atherosclerotic Cardiovascular Disease. *Am Heart J*. 2022 Jul; **249**:12-22. doi: 10.1016/j.ahj.2022.03.006. Epub 2022 Mar 19. PMID: 35318028; PMCID: PMC9976623.
13. Yakovchenko V, Morgan TR, Chinman MJ, Powell BJ, Gonzalez R, Park A, Malone PS, Chartier M, **Ross D**, Rogal SS. Mapping the road to elimination: a 5-year evaluation of implementation strategies associated with hepatitis C treatment in the veterans health administration. *BMC Health Serv Res*. 2021 Dec 18; **21(1)**:1348.
14. Gonzalez R, Park A, Yakovchenko V, Rogal S, Chartier M, Morgan TR, **Ross D**. HCV Elimination in the US Department of Veterans Affairs. *Clin Liver Dis (Hoboken)*. 2021 Aug 18; **18(1)**:1-6.
15. Rogal SS, Yakovchenko V, Gonzalez R, Park A, Beste LA, Rozenberg-Ben-Dror K, Bajaj JS, Scott D, McCurdy H, Comstock E, Sidorovic M, Gibson S, Lamorte C, Nobbe A, Chartier M, **Ross D**, Dominitz JA, Morgan TR. The Hepatic Innovation Team Collaborative: A Successful Population-Based Approach to Hepatocellular Carcinoma Surveillance. *Cancers (Basel)*. 2021 May 7; **13(9)**:2251.
16. Rogal SS, Yakovchenko V, Morgan T, Bajaj JS, Gonzalez R, Park A, Beste L, Miech EJ, Lamorte C, Neely B, Gibson S, Malone PS, Chartier M, Taddei T, Garcia-Tsao G, Powell BJ, Dominitz JA, **Ross D**, Chinman MJ. Getting to implementation: a protocol for a Hybrid III stepped wedge cluster randomized evaluation of using data-driven implementation strategies to improve cirrhosis care for Veterans. *Implement Sci*. 2020 Oct 21; **15(1)**:92.

Published Articles (cont.)

17. Beste LA, Maier MM, Borgerding J, Lowy E, Hauser RG, Van Epps P, Ohl M, **Ross D**, Chartier M. Testing Practices and Incidence of Chlamydial and Gonococcal Infection in the Veterans Health Administration, 2009-2019. *Clin Infect Dis*. 2021 Nov 2; **73(9)**:e3235-e3243.
18. Rogal SS, Yakovchenko V, Gonzalez R, Park A, Lamorte C, Gibson SP, Chartier M, **Ross D**, Comstock E, Bajaj JS, Morgan TR. Characterizing patient-reported outcomes in veterans with cirrhosis. *PLoS One*. 2020 Sep 1; **15(9)**:e0238712.
19. Yakovchenko V, Miech EJ, Chinman MJ, Chartier M, Gonzalez R, Kirchner JE, Morgan TR, Park A, Powell BJ, Proctor EK, **Ross D**, Waltz TJ, Rogal SS. Strategy Configurations Directly Linked to Higher Hepatitis C Virus Treatment Starts: An Applied Use of Configurational Comparative Methods. *Med Care*. 2020; **58(5)**:e31-e38.
20. Rogal SS, Yakovchenko V, Waltz TJ, Powell BJ, Gonzalez R, Park A, Chartier M, **Ross D**, Morgan TR, Kirchner JE, Proctor EK, Chinman MJ. Longitudinal assessment of hepatitis C treatment. Year 2. *Implement Sci*. 2019 Apr 8; **14(1)**:36.
21. Butt AA, Yan P, Lo Re V, Shaikh O, **Ross DB**. Trends in Treatment Uptake and Provider Specialty for Hepatitis C Virus (HCV) Infection in the Veterans Affairs Healthcare System: Results from the Electronically Retrieved Cohort of HCV-Infected Veterans (ERCHIVES). *Clin Infect Dis*. 2019 Feb 15; **68(5)**:857-859.
22. Belperio PS, Chartier M, Gonzalez RI, Park AM, **Ross DB**, Morgan TR, Backus LI. Hepatitis C Care in the Department of Veterans Affairs: Building a Foundation for Success. *Infect Dis Clin North Am*. 2018 Jun; **32(2)**:281-292.
23. Bajaj JS, **Ross D**. Concise Commentary: Remaining Outside the Hospital Is a Golden State in Cirrhosis-Lessons from California. *Dig Dis Sci*. 2018 Sep; **63(9)**:2275-6.
24. Belperio PS, Chartier M, **Ross DB**. After Curing Hepatitis C Infection. *Ann Intern Med* 2018; **168(9)**:682-3.
25. Park A, Gonzalez R, Chartier M, Rogal S, Yakovchenko V, **Ross D**, Morgan TR. Screening and Treating Hepatitis C in the VA: Achieving Excellence Using Lean and System Redesign. *Fed Pract*. 2018 Jul; **35(7)**:24-29.

Published Articles (cont.)

26. Chartier M, Maier MM, Morgan TR, Lowy E, Hoffman-Högg L, **Ross D**, Beste LA. Achieving Excellence in Hepatitis B Virus Care for Veterans in the Veterans Health Administration. *Fed Pract*. 2018 Mar; **35(Suppl 2):S49-S53**.
27. Belperio PS, Chartier M, **Ross DB**, Alaigh P, Shulkin D. Curing Hepatitis C Virus Infection: Best Practices from the U.S. Department of Veterans Affairs. *Ann Intern Med* 2017 Oct 3; **167(7):499-504**.
28. Rogal SS, Yakovchenko V, Waltz TJ, Powell BJ, Kirchner JE, Proctor EK, Gonzalez R, Park A, **Ross D**, Morgan TR, Chartier M, Chinman MJ. The association between implementation strategy use and the uptake of Hepatitis C treatment in a national sample. *Implement Sci* 2017 May 11; **12(1):60**.
29. Beste LA, Glorioso TJ, Ho PM, Au DH, Kirsh SR, Todd-Stenberg J, Chang MF, Dominitz JA, Barón AE, **Ross D**. Telemedicine Specialty Support Promotes Hepatitis C Treatment by Primary Care Providers in the Department of Veterans Affairs. *Am J Med* 2017; **130(4):432-438**.
30. **Ross DB**, Belperio PS, Chartier M, Backus LI. Hepatitis C Testing in U.S. Veterans Born 1945-1965: An Update. *J Hepatol* 2017; **66(1):237-8**.
31. Maier MM, **Ross DB**, Chartier M, Belperio PS, Backus LI. Cascade of Care for Hepatitis C Virus Infection Within the US Veterans Health Administration. *Am J Public Health* 2014 Feb; **106(2):353-8**.
32. Beste LA, Leipertz SL, Grollman PK, Dominitz JA, **Ross D**, Ioannou GN. Trends in Burden of Cirrhosis and Hepatocellular Carcinoma by Underlying Liver Disease in US Veterans, 2001-2013. *Gastroenterology*. 2015 Nov; **149(6):1471-1482**.
33. Backus L, Zuckerman M, Yip G, Thomas BP, Torres M, Bell T, **Ross D**. HIV Care Continuum Applied to the US Department of Veterans Affairs: HIV Virologic Outcomes in an Integrated Health Care System. *J Acquir Immune Defic Syndr*. 2015 Aug 1; **69(4):474-80**.
34. Chartier M, Blais R, Steinberg T, Catella S, Dehon S, **Ross D**, Zeiss R. A Postdoctoral Psychology Fellowship in Integrated HIV and Hepatitis C Clinical Care: Rationale, Progress, and Future Directions. *Training and Education in Professional Psychology* 2015 May; **9(2): 77-84**.
35. Beste LA, Ioannou GN, Yang Y, Chang M, **Ross D**, Dominitz J. Improved Surveillance for Hepatocellular Carcinoma with a Primary Care-Oriented Clinical Reminder. *Clin Gastroenterol Hepatol*. 2015 Jan; **13(1):172-9**.

Published Articles (cont.)

36. Midboe AM, Elwy AR, Durfee JM, Gifford AL, Yakovchenko V, Martinello RA, **Ross D**, Czarnogorski M, Goetz MB, Asch SM. Building Strong Research Partnerships Between Public Health and Researchers: A VA Case Study. *J Gen Intern Med*. 2014 Dec; **29 Suppl 4**:831-4.
37. Atkins D, **Ross D**, Kelley M. Acting in the Face of Uncertainty. *Ann Intern Med* 2014; **161(4)**:300-1.
38. Belperio P, Backus L, **Ross D**, Neuhauser M, Mole L. A Population Approach to Disease Management: Hepatitis C Direct Acting Antiviral Use in a Large Healthcare System. *J Managed Care Pharm* 2014 Jun; **20(6)**:533-40.
39. Czarnogorski M, Halloran J, Pedati C, Dursa EK, Durfee J, Martinello R, Davey V, **Ross D**. Expanded HIV testing in the US Department of Veterans Affairs, 2009-2011. *Am J Public Health* 2013 Dec; **103(12)**:e40-5.
40. **Ross D**. Treatment of veterans with hepatitis C in the United States Department of Veterans Affairs. *J Hepatol* 2013 Jul; **59(1)**:196.
41. Yee HS, Chang MF, Pocha C, Lim J, **Ross D**, Morgan TR, Monto A. Update on the Management and Treatment of Hepatitis C Virus Infection: Recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. *Am J Gastroenterol* 2012; **107(5)**:669-8.
42. Halloran J, Czarnogorski M, Dursa E, Volpp B, Durfee J, Valdiserri R, Davey V, **Ross D**. HIV Testing in the US Department of Veterans Affairs: 2009-2010. *Arch Int Med* 2012 Jan 9; **172(1)**:61-2.
43. McInnes DK, Solomon JL, Bokhour BG, Asch SM, **Ross D**, Nazi KM, Gifford AL. Use of electronic personal health record systems to encourage HIV screening: an exploratory study of patient and provider perspectives. *BMC Res Notes* 2011 Aug 15; **4**:295.
44. Peters R G, Perrillo RP, Jacobson IM, **Ross DB**, Doo EC, Murray JS, Wong J. Entering the new era of therapy for HBV and HCV infections. *J Fam Pract* 2010 Apr; **59(4 Suppl)**: S51-8.
45. Valdiserri RO, Nazi K, McInnes DK, **Ross D**, Kinsinger L. Need to improve routine HIV testing of U.S. Veterans in care: Results of an Internet survey. *J Community Health* 2010; **35(3)**:215-9.

Published articles (cont.)

46. Garcia-Tsao G, Lim JK; Monto A, Yee H, Durfee J, Dieperink E, Dominitz J, **Ross D**, Valdiserri R. Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. *Am J Gastroenterol* 2009 Jul; **104(7)**:1802-29.
47. Modak R, **Ross D**, Kan V. Macrolide and Clindamycin Resistance in *Staphylococcus aureus* Isolates. *Infect Control Hosp Epidemiol* 2008; **29**:180-2.
48. **Ross D**. Review of “Overdose: How excessive government regulation stifles pharmaceutical innovation.” *J Clin Invest* 2007; **117**:3598-359.
49. **Ross D**. The FDA and the case of Ketek. *New Engl J Med* 2007; **356**:1601-1604.
50. Powers JH, Lin D, **Ross D**. FDA evaluation of antimicrobials: subgroup analysis. *Chest* 2005; **127**: 2298-9.
51. Powers JH, Cooper CK, Lin D, **Ross DB**. Sample size and the ethics of non-inferiority trials. *Lancet*. 2005; **366**:24-5.
52. Powers JH, **Ross DB**, Lin D. Letter to the Editor: Linezolid and Vancomycin for Methicillin-Resistant *Staphylococcus aureus* Nosocomial Pneumonia: The Subtleties of Subgroup Analyses. *Chest* 2004; **126**:314- 315.
53. Powers JH, **Ross DB**, Brittain L, Albrecht R, and Goldberger MJ. The United States Food and Drug Administration and Noninferiority Margins in Clinical Trials of Antimicrobial Agents. *Clin Inf Dis* 2002; **34**:879- 881.
54. Qunibi W, Al-Furayh O, Almeshari K, Lin S-F, Sun R, Heston L, **Ross D**, Rigsby M, and Miller G. Serologic association of human herpesvirus eight with posttransplant Kaposi’s sarcoma in Saudi Arabia. *Transplantation* 1998; **65**:583-585.
55. **Ross DB** and Ziff EB. Differential production of human adenovirus late transcription unit mRNAs during abortive infections in monkey cells. *Virology* 1994; **202**:107-115.
56. **Ross DB** and Ziff EB. Defective synthesis of early region 4 mRNAs during abortive human adenovirus infections in monkey cells. *J Virol* 1992; **66**:3110-3117.